Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Nombreux kystes dermiques asymptomatiques: Diagnostic et traitement des stéatocystomes multiples.

Georgakopoulos JR, Ighani A, Yeung J.

Can Fam Physician. 2018 Dec;64(12):e517-e525. Review. French.

PMID:
30541816
Free Article
2.

Numerous asymptomatic dermal cysts: Diagnosis and treatment of steatocystoma multiplex.

Georgakopoulos JR, Ighani A, Yeung J.

Can Fam Physician. 2018 Dec;64(12):892-899. Review.

3.

Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.

Georgakopoulos JR, Phung M, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov 18:1203475418814229. doi: 10.1177/1203475418814229. [Epub ahead of print]

PMID:
30449146
4.

A case of rituximab-induced pyoderma gangrenosum.

Georgakopoulos JR, Rohekar G, Lovegrove FE.

JAAD Case Rep. 2018 Oct 29;4(10):979-981. doi: 10.1016/j.jdcr.2018.09.003. eCollection 2018 Nov. No abstract available.

5.

Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials.

Georgakopoulos JR, Ighani A, Phung M, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(6):647-649. doi: 10.1177/1203475418782135. No abstract available.

PMID:
30322297
6.

Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.

Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J.

Br J Dermatol. 2019 Jan;180(1):211-212. doi: 10.1111/bjd.17099. Epub 2018 Oct 10. No abstract available.

PMID:
30120892
7.

Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study.

Georgakopoulos JR, Phung M, Ighani A, Lam K, Yeung J.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e7-e8. doi: 10.1111/jdv.15100. Epub 2018 Jun 20. No abstract available.

PMID:
29846974
8.

Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.

Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J.

J Am Acad Dermatol. 2018 Nov;79(5):953-956. doi: 10.1016/j.jaad.2018.04.043. Epub 2018 May 4. No abstract available.

PMID:
29730366
9.

Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review.

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

PMID:
29707979
10.

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series.

Phung M, Georgakopoulos JR, Ighani A, Giroux L, Yeung J.

JAAD Case Rep. 2018 Mar 31;4(4):310-313. doi: 10.1016/j.jdcr.2017.11.006. eCollection 2018 May. No abstract available.

11.

Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.

Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J.

J Cutan Med Surg. 2018 May/Jun;22(3):290-296. doi: 10.1177/1203475418755982. Epub 2018 Jan 26.

PMID:
29373924
12.

Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.

Georgakopoulos JR, Phung M, Ighani A, Yeung J.

J Am Acad Dermatol. 2018 Jul;79(1):155-157. doi: 10.1016/j.jaad.2018.01.003. Epub 2018 Jan 4. No abstract available.

PMID:
29307635
13.

Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.

Georgakopoulos JR, Ighani A, Phung M, Yeung J.

J Am Acad Dermatol. 2018 May;78(5):1019-1020. doi: 10.1016/j.jaad.2017.11.036. Epub 2017 Nov 24. No abstract available.

PMID:
29180095
14.

Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study.

Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J.

J Am Acad Dermatol. 2018 Apr;78(4):801-803. doi: 10.1016/j.jaad.2017.09.067. Epub 2017 Oct 7. No abstract available.

PMID:
29017843
15.

A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.

Ighani A, Georgakopoulos JR, Walsh S, Shear NH, Yeung J.

J Am Acad Dermatol. 2018 Mar;78(3):623-626. doi: 10.1016/j.jaad.2017.09.060. Epub 2017 Oct 6. No abstract available.

PMID:
28989112
16.

Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.

Georgakopoulos JR, Ighani A, Zhou LL, Yeung J.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32-e34. doi: 10.1111/jdv.14468. Epub 2017 Aug 2. No abstract available.

PMID:
28695989
17.

Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report.

Georgakopoulos JR, Ighani A, Yeung J.

J Cutan Med Surg. 2017 Sep/Oct;21(5):452-456. doi: 10.1177/1203475417712499. Epub 2017 May 23.

PMID:
28535721
18.

The chemoattractant potential of ginsenosides in the ginseng - Pythium irregulare pathosystem.

Ivanov DA, Georgakopoulos JRC, Bernards MA.

Phytochemistry. 2016 Feb;122:56-64. doi: 10.1016/j.phytochem.2015.11.005. Epub 2015 Nov 19.

PMID:
26608666

Supplemental Content

Loading ...
Support Center